Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; the best sentinel lymph node biopsy technique for patients with node-positive disease who convert to node-negative disease with neoadjuvant chemotherapy; whether immunohistochemistry should be routinely used for sentinel lymph node evaluation; and the role of radiation therapy in this patient population.
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs ch...
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative b...
Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with...
Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gen...
Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to...